Similar articles

• [Current problems of active substance research. 3. Structure-activity relationships of angiotensin II and analog].

  Piesche L, Hilse H, Scheer E. Piesche L, et al. Pharmazie. 1974 Apr;29(4):233-51. Pharmazie. 1974. PMID: 4152658 Review. German. No abstract available.
• [Pharmacological study of pipratecol (JP 711) and of a pharmaceutical combination raubasine-JP 711].

  Laubie M, Le Douarec JC. Laubie M, et al. Arzneimittelforschung. 1969 Nov;19(11):1820-6. Arzneimittelforschung. 1969. PMID: 4391788 French. No abstract available.
• Effects of angiotensin on the central nervous system.

  Severs WB, Daniels-Severs AE. Severs WB, et al. Pharmacol Rev. 1973 Sep;25(3):415-49. Pharmacol Rev. 1973. PMID: 4356083 Review. No abstract available.
• Neurogenic hypertension, with special reference to the central neurogenic effects of angiotensin.

  Dickinson CJ. Dickinson CJ. Circ Res. 1970 Oct;27:Suppl 2:169+. Circ Res. 1970. PMID: 4319093 No abstract available.
• [Therapy of hypertension. I. new antihypertensive agents, pharmacologic and pharmacokinetic bases. Beta-adrenergic blockers and blood pressure lowering].

  Brunner H. Brunner H. Verh Dtsch Ges Kreislaufforsch. 1977;43:75-86. Verh Dtsch Ges Kreislaufforsch. 1977. PMID: 26152 Review. German. No abstract available.